Progressive Malignant Insulinoma with Multiple Liver Metastases: A Case Report
Novelty in Biomedicine,
Vol. 12 No. 3 (2024),
6 July 2024
,
Page 121- 126
https://doi.org/10.22037/nbm.v12i3.44177
Abstract
Background: Insulin-secreting tumors are the most common hormone-producing neoplasm of the gastrointestinal tract. Only 10 percent of overall cases of insulinoma have malignant variants, which have a poor prognosis.
Cases Report: The present study reports an unusual case of pancreatic neuroendocrine tumor associated with hypoglycemia and liver metastasis as the initial presentation followed a rapidly progressive clinical course. A few cases of malignant insulinoma were reported with favorable responses in the literature. This research presents a patient with resistant malignant insulinoma who could not undergo an operation and received treatment with somatostatin analogs (S.S.A.), Peptide Receptor Radionuclide Therapy (PRRT), and other supportive care that was inappropriate.
Conclusion: Early diagnosis and extensive treatment are auspicious for improving the prognosis of malignant insulinoma, and proper treatment with medications would increase the quality of life of patients. Nevertheless, unfortunately, late patient referrals, socioeconomic conditions, and being infected with Covid-19 disease resulted in death.
- Metastasis
- Malignant insulinoma
- Hypoglycemia
How to Cite
References
Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, et al. Diagnosis and management of insulinoma. World J Gastroenterol. 2013;19(6):829-37.
Baudin E, Caron P, Lombard-Bohas C, Tabarin A, Mitry E, Reznick Y, et al. Malignant insulinoma: recommendations for characterisation and treatment. Ann Endocrinol (Paris). 2013;74(5-6):523-33.
Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system: WHO; 2010.
Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol. 2010;6(2):229-37.
Abboud B, Boujaoude J. Occult sporadic insulinoma: localization and surgical strategy. World J Gastroenterol. 2008;14(5):657-65.
Öberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23.
Laura Burns,Bita Naimi,Matthew Ronan,Huihong Xu andHorst Christian Weber ,et al. Report of a Novel Molecular Profile in Malignant Insulinoma. J Clin Med. 2023;12(4):1280.
Bertani E, Fazio N, Botteri E, Chiappa A, Falconi M, Grana C, et al. Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach. Surgery. 2014;155(4):607-14.
Brown E, Watkin D, Evans J, Yip V, Cuthbertson DJ. Multidisciplinary management of refractory insulinomas. Clin Endocrinol (Oxf). 2018;88(5):615-24.
Rindi G, Klöppel G, Alhman X, Caplin M, Couvelard A, De Herder W, et al. T.N.M. staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449(4):395-401.
Zarei M, Dastras M, Roshanravan M. A non-secretory malignant insulinoma: a case report. Biomedical Research and Therapy. 2019;6(3):3093-5.
Dimitriadis GK, Weickert MO, Randeva HS, Kaltsas G, Grossman A. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2016;23(9):423-36.
Falconi M, Eriksson B, Kaltsas G, Bartsch D, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153-71.
Network, N.C.C. Neuroendocrine Tumors. Symptoms Causes. 2021;3:2021.
Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31(3):271-9.
Verma Priyanka MBBS, Malhotra DNB, Gaurav DRM, Manjunath H, et al. Complete Resolution of Disease After Peptide Receptor Radionuclide Therapy in a Patient of Metastatic Insulinoma, Clin Nucl Med. 2022;47(1):77-8.
Yilmaz E, Engin MN, Özkan ZG, Kovan B, Büyükkaya F, Poyanli A, et al. Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not? Nucl Med Commun. 2020;41(12):1242-9.
Maja Cigrovski Berkovic, Monika Ulamec, Sonja Marinovic, Ivan Balen,et al. Malignant insulinoma: Can we predict the long-term outcomes? World J Clin Cases. 2022;10(16):5124-32.
N Engl J Med. 2011;364(6):514-23.
Liu Q, Duan J, Zheng Y, Luo J, Cai X, Tan H. Rare malignant insulinoma with multiple liver metastases derived from ectopic pancreas: 3-year follow-up and literature review. Onco Targets Ther. 2018;11:1813-9.
Bozkirli E, Bakiner O, Abali H, Andic C, Yapar AF, Kayaselcuk F, et al. A case of inoperable malignant insulinoma with resistant hypoglycemia who experienced the most significant clinical improvement with everolimus. Case Rep Endocrinol. 2013;2013:636175.
- Abstract Viewed: 232 times
- pdf Downloaded: 165 times